• Creative Medical Technology Holdings reported a 93% response rate for investigational cell-free therapy Ultrasome in a 30-patient knee osteoarthritis study.
• Group-average pain scores fell approximately 65% over six months; average WOMAC scores measuring osteoarthritis symptoms declined 52%.
• Average knee-related quality-of-life scores rose approximately 35 points; no serious adverse events were reported during six months of follow-up.
• The open-label, single-arm pilot had no randomized or sham-controlled comparator.
• Laboratory studies showed significant reductions in markers associated with cartilage degradation and inflammatory signaling, supporting further platform development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200915PRIMZONEFULLFEED9848735) on October 20, 2026, and is solely responsible for the information contained therein.